In today’s complex pharmaceutical landscape, a brand’s market access can no longer be judged solely by its coverage. Pharma leaders are under growing pressure not just to identify access barriers, but to prove their impact. They want the ability to link payer policy decisions to patient outcomes, as their payer strategies and competitive positioning depend upon this kind of actionable intelligence.
This shift in focus demands a new level of visibility across the healthcare ecosystem, as market access teams often struggle to demonstrate how access dynamics impact the patient journey. Market access teams rely primarily on policy and restriction data to understand coverage dynamics. While payer data reveals the rules of market access—from a brand’s formulary status to the various restrictions imposed by the payer—it doesn’t reveal how those rules play out for patients in real time.
To understand the intricacies of the patient experience, market access teams need real-world data. Claims, labs, and EMR data (both structured and unstructured) serve as the connective tissue that links payer decisions and patient outcomes. Taken together, market access research coupled with insights from these RWD sources helps pharma companies identify and mitigate access roadblocks.
Real-World Data Illuminates the Patient Journey
If payer policy data delineates the rules of market access, retrospective claims reveal what happened in reality. Pharma teams tend to rely on claims data to measure their brands’ uptake, but claims alone do not provide any context for why something happened.
To close that gap, manufacturers can turn to physician-authored EMR notes, which provide a narrative of the patient journey. These notes capture provider frustrations, documentation of delays, and patient-level reasons for nonadherence or discontinuation of a medication. When synthesized alongside structured EMR data, these clinical notes reveal the human context behind every coverage statistic.
For example, a claim might indicate that a prescription was denied, but it doesn’t explain the reasons behind a denial code—or what happened next. A physician’s clinical notes, on the other hand, might show that the denial led to a two-week treatment delay, or that the patient ultimately abandoned therapy due to high out-of-pocket cost. That’s the level of detail needed to turn access analytics into patient-impact evidence.
Identifying Access Friction Points with Real-World Data
As pharma companies know, there’s often a significant disconnect between a payer’s stated management policies for a brand and what happens in the real world. By combining market research insights with RWD signals, manufacturers can get a better understanding of how payer perceptions and decisions impact patient behavior.
With the use of advanced query tools, market access teams do not need to wade through reams of RWD in order to find what they’re looking for. For example, by searching for specific keywords in unstructured EMR data—like “medical exception” or a particular brand name—teams can pinpoint moments of access friction as they occurred.
After surfacing access challenges from the provider’s point of view, pharma teams can then tailor their engagement strategies accordingly. For example, if EMR analysis reveals frequent mentions of “insurance delay” among a subset of prescribers, account teams can prioritize outreach in those regions or hospitals. Likewise, if patients are declining therapy due to cost, brand teams can strengthen messaging around financial assistance programs.
Coupling market access research with RWD signals helps pharma teams:
Quantify the impact of payer policies on the patient journey: Pairing coverage data with RWD sources helps market access teams measure the definitive impact of payer policy shifts on patient access. By acquiring hard evidence, a brand team can then engage payers and PBMs to support its account strategy. For example, by sharing the fact that a payer’s addition of multiple step edits for Brand B resulted in a 12% decrease in market share over the last quarter, a market access team may be able to persuade the payer to ease its restrictions.
Connect payer sentiment with actual prescribing barriers: By complementing payer sentiment research with real-world data signals from claims, labs and EMRs, market access teams can investigate the downstream impact of payer perspectives and coverage choices. For example, a payer on a panel might report that prescribers will not be pressured to move patients from a legacy product onto a new biosimilar. However, RWD signals might indicate otherwise, revealing that physicians are struggling with inconsistent access to that legacy brand, as prior authorizations are suddenly being denied.
Tailor messaging to physician-identified access challenges: Unstructured EMR data is an especially excellent source for identifying real-world access barriers—such as coverage confusion, delays and appeals, and insurance mandates—documented at the point of care. Once a market access team understands the specific challenges physicians are facing, they can create targeted education campaigns to support HCPs and boost prescriptions. The same RWD sources can be used to track changes over time, giving market access teams insights into whether their provider programs are improving access.
Identify abandonment hotspots and access barriers: By overlaying the longitudinal patient journey with access events—from diagnosis to prescription, authorizations to fulfillment—pharma teams can pinpoint common drop-off points. Are patients abandoning therapy because prior authorizations are frequently denied? Are patients never starting therapy due to the incorrect diagnostic test being ordered?
Validate market research with layered real-world evidence: Pharma has long conducted payer panels, surveys, and message testing to understand market dynamics—but the insights gained from such research often lack tangible validation. Whether a pharma company is using a P&T panel for competitive intelligence or surveying HCPs about message recall, adding complementary RWD signals provides much richer results. For example, a manufacturer might find that its new messaging is stickier than expected when they see it reflected in physician notes.
Driving Better Outcomes with a Unified View of the Patient Experience
For pharma companies, the value of linking market access information to patient outcomes is strategic. Once a brand team understands how and why patient access is blocked, it can design interventions to remove these barriers. The convergence of access intelligence and RWD marks a turning point for the industry. For the first time, pharma companies can connect the dots between payer decisions, provider behavior, and patient experience—within a single analytical framework.
Imagine a future where every formulary restriction and prior authorization policy can be traced to its clinical consequence: treatment delays quantified in days, adherence measured in months, and patient outcomes visible across the care continuum. That’s the power of integrating market access and real-world data. When pharma companies have tangible proof of how payer policies shape the care experience, they can use that knowledge to drive better access for patients in need of their therapies.
Learn more about MMIT’s Custom Market Research, Message Monitor, and P&T Perspectives market research solutions, which can all be paired with real-world data to help your team improve patient access.
